Recent statistics from the NHS have highlighted an increase in prescribed medicine for attention deficit hyperactivity disorder (ADHD) over the past year,
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
